REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., — February 03, 2022 — Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced today that it has appointed Ma’an Muhsin, M.D., as President and Chief Medical Officer of Kriya Oncology™, the company’s oncology therapeutic area division. Dr. Muhsin will lead overall strategic, development, and partnership activities to accelerate and expand Kriya’s portfolio of transformative gene therapies for cancers of high unmet need.
“Ma’an brings a wealth of experience in the development of novel oncology therapies across a number of modalities,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. “He is uniquely positioned to accelerate the expansion and clinical translation of our growing pipeline of gene therapies that can be combined with existing and emerging standards of care in oncology. We are keen to bring forward in vivo gene therapy as a new modality to treat cancer, and Ma’an is a leader with an exceptional track record that will help us achieve this goal.”
Dr. Muhsin previously served as Chief Medical Officer at Medicenna Therapeutics where he designed and executed clinical trials of the company’s solid tumor programs. Prior to joining Medicenna, he served as Medical Lead, Oncology Clinical Development for Nektar Therapeutics where he oversaw the progression of the PIVOT-12 and REVEAL clinical studies for metastatic melanoma and advanced and local solid tumors, respectively. Dr. Muhsin has held roles of increasing responsibility at HUYA Bioscience International where he served as the Senior Vice President, Oncology Clinical Development, and at Halozyme Therapeutics where he served as Senior Medical Director, Oncology Clinical Development. He also worked in the U.S. Army Combat Support Hospitals (CSH) and held other positions within the Medical Brigade and the Medical Command under the United States Department of Defense (DoD). Dr. Muhsin completed his medical education at the Baghdad University School of Medicine and completed postgraduate education in oncology drug development at Tufts University Center for the Study of Drug Development (CSDD).
“I am excited to join Kriya and look forward to advancing its promising portfolio of gene therapies in oncology,” said Dr. Muhsin. “While the management of cancer has come a long way in the last decade, I believe in the potential to further enhance the treatment of patients with the incorporation of rationally engineered gene therapies that can transform treatment paradigms for a wide array of cancers. I look forward to leveraging Kriya’s fully-integrated gene therapy engine to deliver a pipeline of novel medicines with the potential to significantly impact the lives of cancer patients.”
Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed, and manufactured, improving speed to market and delivering significant reductions in cost. Kriya is organized into four principal business units: Kriya Technologies™, Kriya Therapeutics™, Kriya R&D™, and Kriya Manufacturing™. The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in ophthalmology, oncology, rare disease, and chronic disease. Kriya was founded by pioneers in the biopharmaceutical industry and is backed by leading life sciences and technology investors. The company has core operations in Silicon Valley, California and Research Triangle Park, North Carolina. For more information, please visit www.kriyatx.com and follow on LinkedIn.